KB-1169

Ramucirumab

12181

Home » Ramucirumab

Background of Ramucirumab

Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2, a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Through blocking activation of VEGFR-2 by VEGF-A and the other VEGF ligands, ramucirumab inhibits the angiogenesis pathways involved in the development and progression of gastric cancer.

Specifications

Catalog Number	KB-1169
Antibody Name	Ramucirumab
Isotype	Human IgG1, kappa
FC Muations	Wild Type
Target	VEGFR2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Cyramza (ramucirumab) package insert. Eli Lilly and Company. 2014 Retrieved from http://www.cyramza.com.
Wadhwa Roopma, Taketa Takashi, Sudo Kazuki, Blum-Murphy Mariela, Ajani Jaffer A. Ramucirumab: a novel antiangiogenic agent. Future Oncology (London, England) 2013;9:789–795.